Mission Statement: Evidence-based Complementary and Alternative Medicine (eCAM) is an international, peer-reviewed journal that seeks to understand the sources and to encourage rigorous research ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis ...

Unlike allergen-induced conditions, CSU is driven by immune system responses and is typically managed symptomatically with antihistamines, antipruritic, and anti-inflammatory treatments. Remibrutinib ...

Preclinical and clinical data indicate seladelpar has anticholestatic, anti-inflammatory, antipruritic, and antifibrotic effects. Seladelpar has potential to help meet the current unmet need of ...

Am J Health Syst Pharm. 2011;68(15):1419-1425. The short duration of activity of naloxone when the drug is administered as an i.v. bolus may limit its effectiveness for the management of OIP ...